A Phase 3 interventional study of Oxycodone extended-release and Placebo of oxycodone extended-release in Moderate-to-severe Chronic Low Back Pain, sponsored by Egalet Ltd. Completed at 74 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-03-05.
Sponsored by Egalet Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 711 studies in Low Back Pain with a site in United States — 99 open to participants now, 125 under way, 3 of them phase 3. Low Back Pain · United States.
Among the 711 studies in Low Back Pain with a site in United States, this one is the 43rd largest by enrollment of the 623 interventional ones that give a count, is one of 25 that started in 2016, is one of 62 in phase 3, and was the 339th registered.
2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.
Browse Low Back Pain studies →99 of the 711 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:
New York Medical College · Sites in United States
Ages 18+
Loma Linda University · Sites in United States
Ages 18–65 · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 18+
University of Central Florida · Sites in United States
Ages 18–65
Eli Lilly and Company · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
711 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 80 · Phase 3 73 · Phase 4 50
First in 1977; this study’s year is marked. 25 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 549 is above the median of 60 across 2,366 interventional studies indexed under Low Back Pain.
Median enrollment 79 across the 623 interventional studies, 89 across the 84 observational. Of the 513 that completed or were terminated, 207 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
156 of 711 have an industry lead sponsor. The 10 most frequent:
Egalet Ltd is the lead sponsor of 20 studies on the registry; none are open to participants now.
Egalet Ltd has 1 study filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
51 of the studies in Low Back Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07254806Phase 3DiscGenics, Inc.A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease | 2027-11-24 |
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT07652944Joe X. ZhangTrial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain. | 2026-11 |
| NCT04730700University of Kansas Medical CenterEvaluation of Multi-Tined Expandable Electrode (MEE) Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management. | 2026-11-30 |
| NCT06007976Mayo ClinicLLLT to Reduce Low Back Pain | 2026-12 |
Add all 51 to your calendar (.ics) → With an account.
Among the 711 studies in Low Back Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the analgesic efficacy of Egalet-002 twice daily (BID) in patients with moderate-to-severe chronic low back pain
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Egalet ADER oxycodone tablet
Drug: Oxycodone extended-release
Egalet ADER oxycodone placebo tablet
Drug: Placebo of oxycodone extended-release
Also known as: Egalet-002, Egalet ADER oxycodone
Measure of Average Pain Intensity past 24 hours, as measured by a 0-10 NPRS using eDiary collection daily at bedtime.
Time frame: 16 weeks
Efficacy: daily (past 24 hours) worst pain intensity score (WPI)
Time frame: 16 Weeks
Safety: Incidence of TEAEs, including those leading to treatment withdrawal, and/or abnormal physical examination findings, vital signs measurements, ECGs, and clinical laboratory test results, related to treatment
Time frame: 16 weeks
The record gives a start of Mar 2016, a primary completion of Aug 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone
Egalet Ltd